Vaccines (May 2022)

Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients Who Were Either Fully Vaccinated with Coronavac or Not: An Analytical, Cross Sectional Study

  • Serap Şimşek Yavuz,
  • Gülşah Tunçer,
  • Özlem Altuntaş-Aydın,
  • Mehtap Aydın,
  • Filiz Pehlivanoğlu,
  • Yeşim Tok,
  • Sevim Mese,
  • Alper Gündüz,
  • Ceyda Geyiktepe Güçlü,
  • İklima Özdoğan,
  • Börçe Hemiş-Aydın,
  • Pınar Soğuksu,
  • Aysun Benli,
  • Seniha Başaran,
  • Kenan Midilli,
  • Haluk Eraksoy

DOI
https://doi.org/10.3390/vaccines10050733
Journal volume & issue
Vol. 10, no. 5
p. 733

Abstract

Read online

COVID-19 vaccines are highly protective against severe disease; however, vaccine breakthrough infections resulting in hospitalization may still occur in a small percentage of vaccinated individuals. We investigated whether the clinical and microbiological features and outcomes were different between hospitalized COVID-19 patients who were either fully vaccinated with Coronovac or not. All hospitalized COVID-19 patients who had at least one dose of Coronavac were included in the study. The oldest unvaccinated patients with comorbidities, who were hospitalized during the same period, were chosen as controls. All epidemiologic, clinical and laboratory data of the patients were recorded and compared between the fully vaccinated and unvaccinated individuals. There were 69 and 217 patients who had been either fully vaccinated with Coronavac or not, respectively. All breakthrough infections occurred in the first 3 months of vaccination. Fully vaccinated patients were older and had more comorbidities than unvaccinated patients. There were minor differences between the groups in symptoms, physical and laboratory findings, anti-spike IgG positivity rate and level, the severity of COVID-19, complications, and clinical improvement rate. The mortality rate of fully vaccinated patients was higher than the mortality rate in unvaccinated patients in univariate analysis, which was attributed to the fact that vaccinated patients were older and had more comorbidities. The severity and clinical outcomes of hospitalized patients with breakthrough COVID-19 after Coronavac vaccination were similar to those of unvaccinated patients. Our findings suggest that the immune response elicited by Coronovac could be insufficient to prevent COVID-19-related severe disease and death within 3 months of vaccination among elderly people with comorbidities.

Keywords